• Login
    • Join
  • FOLLOW:
  • Subscribe Free
    • Magazine
    • eNewsletter
    Checkout
    • Magazine
    • News
    • Manufacturing
    • Packaging
    • Development
    • Compliance
    • Top 25
    • Directory
    • Microsites
    • Events
    • More
  • Magazine
  • News
  • Manufacturing
  • Packaging
  • Development
  • Compliance
  • Top 25
  • Directory
  • Microsites
  • Events
  • Current / Back Issue
    Features
    Editorial
    Columns
    Digital Edition
    eNewsletter Archive
    Our Team
    Editorial Guidelines
    Subscribe Now
    Advertise Now
    Top Features
    Hygienic Packaging Technology

    Trends in Solid Oral Dosage Delivery

    5 Reasons Paper Has No Place in Contract Manufacturing

    Injectable Drug Delivery Trends

    Pharmaceutical Manufacturing Equipment Trends
    Breaking News
    Online Exclusives
    Industry News
    Collaborations & Alliances
    Promotions & Moves
    Trials & Filings
    Financial Reports
    Bio News & Views
    Custom Sourcing News
    Packaging & Tracking
    CRO News
    Live From Shows
    Top News
    Innoforce and dMed Enter Development Collaboration

    Matica Biotechnology Breaks Ground on Cell and Gene Therapy Site

    Four Female Leaders Appointed to Cell & Gene CDMO

    Fusion Pharmaceuticals Acquires IPN-1087

    Strata Oncology Unveils Strata PATH Trial
    APIs
    Aseptic Processing
    Cleaning Validation
    Clinical Trial Materials
    Cytotoxics and High Potency Manufacturing
    Equipment
    Excipients
    Extractables and Leachables
    Facilities
    Fill/Finish
    Lyophilization
    Parenterals
    Process Development
    Process Validation
    Risk Management
    Scale-up/ Technology Transfer
    Solid Dosage/ Creams/ Ointments

    Matica Biotechnology Breaks Ground on Cell and Gene Therapy Site

    WuXi AppTec Completes OXGENE Acquisition

    Trends in Solid Oral Dosage Delivery

    Injectable Drug Delivery Trends

    Oral Solids: Market & Technology Trends
    Capsules
    Cold Chain Management
    Injectables
    Logistics
    Serialization
    Solid Dosage / Semi-solids
    Supply Chain
    Vials

    Hygienic Packaging Technology

    Reshaping the Pharmaceutical Supply Chain

    Serialization: Level 5 Solution

    Covectra Introduces Next-Gen Serialization Solution

    Bormioli Opens New Glass Research Center
    Analytical Services
    Bioanalytical Services
    Bioassay Developement
    Biologics, Proteins, Vaccines
    Biosimilars
    Chemistry
    Clinical Trials
    Drug Delivery
    Drug Development
    Drug Discovery
    Formulation Development
    Information Technology
    Laboratory Testing
    Methods Development
    Microbiology
    Preclinical Outsourcing
    R&D
    Toxicology

    Innoforce and dMed Enter Development Collaboration

    Matica Biotechnology Breaks Ground on Cell and Gene Therapy Site

    Four Female Leaders Appointed to Cell & Gene CDMO

    Strata Oncology Unveils Strata PATH Trial

    Alimentiv Acquires McDougall Scientific
    Filtration & Purification
    GMPs/GCPs
    Inspections
    QA/QC
    Regulatory Affairs
    Validation

    Guide to Maintaining Validation of Older Facilities: Why, When and How

    The Year of COVID: How FDA Coped with a Worldwide Pandemic in 2020 and What to Expect in 2021

    Top BioPharma Form Accumulus Synergy

    Global Biosciences Co. Selects ValGenesis VLMS

    Gene Therapy Co. Selects ValGenesis' SaaS Platform
    Companies
    Categories
    Corporate Capabilities
    Add New Company
    Contract Service Directory Companies
    Baxter BioPharma Solutions

    PCI Pharma Services

    Reed-Lane

    Emergent BioSolutions

    Adare Pharma Solutions
    Companies
    News Releases
    Posters
    Brochures
    Services
    Videos
    Case Study
    White Papers
    Jobs
    Contract Service Directory Companies
    Syngene

    Cytovance Biologics

    Aphena Pharma Solutions

    PCI Pharma Services

    Baxter BioPharma Solutions
    Webinars
    Live From Shows
    • Magazine
      • Current / Back Issue
      • Features
      • Editorial
      • Columns
      • Editorial Guidelines
      • Subscribe Now
      • Advertise Now
      • Enewsletter Archive
      • Digital Edition
    • Directory
      • Companies
      • Categories
      • Corporate Capabilities
      • Add Your Company
    • Manufacturing
      • APIs
      • Aseptic Processing
      • Cleaning Validation
      • Clinical Trial Materials
      • Cytotoxics and High Potency Manufacturing
      • Equipment
      • Excipients
      • Extractables and Leachables
      • Facilities
      • Fill/Finish
      • Lyophilization
      • Parenterals
      • Process Development
      • Process Validation
      • Risk Management
      • Scale-up/ Technology Transfer
      • Solid Dosage/ Creams/ Ointments
      • cGMP Manufacture
    • Packaging
      • Capsules
      • Cold Chain Management
      • Injectables
      • Logistics
      • Serialization
      • Solid Dosage / Semi-solids
      • Supply Chain
      • Vials
    • Development
      • Analytical Services
      • Bioanalytical Services
      • Bioassay Developement
      • Biologics, Proteins, Vaccines
      • Biosimilars
      • Chemistry
      • Clinical Trials
      • Drug Delivery
      • Drug Development
      • Drug Discovery
      • Formulation Development
      • Information Technology
      • Laboratory Testing
      • Methods Development
      • Microbiology
      • Preclinical Outsourcing
      • R&D
      • Toxicology
    • Compliance
      • Filtration & Purification
      • GMPs/GCPs
      • Inspections
      • QA/QC
      • Regulatory Affairs
      • Validation
    • Top 25 Pharma & BioPharma
    • Contract Pharma Direct
    • Breaking News
    • Online Exclusives
    • Slideshows
    • Experts Opinions
    • Surveys
      • Outsourcing Survey
      • Salary Survey
    • Glossary
    • Videos
    • Podcasts
    • White Papers
    • Infographics
    • Contract Pharma Conference
      • Contract Pharma Conference
      • Speakers
      • Exhibitors
      • Conference Sessions
    • Supplier Microsite
      • Companies
      • News Releases
      • Posters
      • Brochures
      • Services
      • Videos
      • Case Study
      • White Papers
    • eBook
    • Webinars
    • Events
      • Industry Events
      • Live from Show Events
      • Webinars
    • Classifieds / Job Bank
      • Classifieds
      • Job Bank
    • About Us
      • About Us
      • Contact Us
      • Advertise With Us
      • Privacy Policy
      • Terms of Use
    Columns

    A Witness to the Growth of Outsourcing

    Observations from the 2019 Contract Pharma Conference.

    A Witness to the Growth of Outsourcing
    Related CONTENT
    • Asymchem
    • Softweb Solutions
    • Vetio Animal Health
    • Akcea, Pfizer Enter Licensing Agreement for Antisense Therapy
    • Contracting And Outsourcing Agenda
    Emil W. Ciurczak, DoraMaxx Consulting10.15.19
    I just attended my first Contract Pharma Conference and I was introduced to a new world. Although I have been in the Pharma industry since 1970, it was almost all with larger companies. When I began my career (Ciba, Summit, NJ), the active pharmaceutical ingredient (API) was usually synthesized in-house, the product made in-house, packaged in-house, stored in our own warehouses and shipped directly to hospitals and pharmacies. And then, blockbusters happened (Valium, Librium, Viagra, and yes, OxyContin) and the companies grew quickly to accommodate the demand. At one point in the early 1990s I believe Pfizer had over 80 sites running, and the other biggies were into M&A, too.

    Then, a funny thing happened; well several, actually:

    1. The major pharma companies became truly international—not just selling to European and U.S. markets—and expanded the supply chain across the globe.

    2. With the spread of markets, several things happened:
      a. First, packaging and distribution were decentralized (ceding record-keeping to contractors)
      b. Then manufacturing and clinical studies were outsourced.
      c. Along the way, manufacturing sites were opened in developing countries.

    This trend away from centralized “doing everything” has generated an entire industry. Contract organizations, and supporting industries, have multiplied exponentially over the last few decades. This is a good thing on many levels:

    1. In a large organization, especially with fewer lots made due to generic competition, there is a fair amount of “down-time” for much of the equipment. With a much higher overhead (wages, HVAC, taxes), it becomes attractive to have routine production of existing products manufactured by a contract manufacturing organization (CMO).

    2. Each specialized CxO can focus on an individual portion of the R&D through sales of a drug product:
      a. One can concentrate on properly synthesizing APIs.
      b. One can focus on clinical studies (smaller batches, heavy paperwork, statistics of patient responses, etc.)
      c. CMO’s have been in existence for years, concentrating on one thing: making the product as well as possible, in a timely manner.

    3. A “cottage industry” of parts/components suppliers has grown around the outsourcing trend. These smaller manufacturers can focus on making better “widgets,” such as bottles, packaging materials, labels, package inserts, and such. This is important because, unlike a smaller number of manufacturing sites (previously only in-house for the larger companies) making larger batches of drugs, we now have many CMOs and generic houses making smaller batches of the same drugs at many locations. This very “smallness” can make them more agile and faster to change over from one manufacturer of product X to another, also making X under a different brand name.

    4. Contract organizations may be located closer to where their output (clinical supplies, API, final products) is needed, lowering supply-chain and shipping charges and complexity. This makes “just-in-time” manufacturing and product deliveries possible.

    From a quality and safety point of view, the contract organization would have a simpler range for, say, the lab personnel. A manufacturer’s lab is simply responsible for analyzing raw materials, in-process and final products, and stability samples. All are usually compendial or modified compendial methods, derived from USP, ASTM, BP, JP, etc. This assures that the products throughout the industry are, at least, consistently analyzed.

    Having said all these nice things, there are some negatives to this diaspora of responsibilities. The pharmaceutical industry, in general, is the most conservative in the world. Of course, it is the most regulated and inspected in the world, so that is one obvious reason for glacier-like pace of change. There are a few other practical reasons for not applying newer technologies:

    1. When a company has almost more orders for a product than it can fill, it spends more time producing lots than finding newer methods of analyses. It has long been seen that the industry uses amazing technology to develop and new API, analyze the blood of clinical patients, and develop a new dosage form.

    At this point, much of the company’s patent life has been used, leaving a relatively short time to make R&D costs back and see a profit. The chance of an NDA (new drug application) being delayed by using “new” analytical methods causes them to continue to use USP-based methods, many dating back decades. This means a natural resistance to PAT/QbD (Process Analytical Technology/Quality by Design) programs.

    2. If the originator of a drug product uses compendial methods, with all the resources available, there is not much chance of a smaller contract organization adopting newer, initially expensive technologies. In addition, adding a methodology after the fact is harder and the CMO seldom has the personnel or time (or permission or desire to submit an ANDA) to develop a new method for a contracted product.

    3. Should a contracted organization desire to apply a newer, non-traditional technology (i.e., Near-Infrared, Raman, or LIF [LASER-induced fluorescence]), it would be most difficult since product clinical studies, final dosage form development, pilot plant scale-up, and production/stability can easily be spread over four locations in four different states, or countries for that matter. Clearly, the technology involved would have to be duplicated over all four locations—mandating validation in all locations—and would be far more expensive, time-consuming, and complex than simply applying it at a single company performing all these functions.

    Another difficulty for a CMO to develop alternative methods is often the sheer number of products a typical site could be producing in a given timeframe. A generic house, for example might file ANDAs for multiple drugs each quarter. Where an initiator company generally only files a few NDAs per years, allowing for sophisticated (alternative) analytical methods (lab and on-line) to be developed. The smaller company, burdened with smaller budgets AND many more products would be less likely to be the point of modernization. So, if the new technology isn’t handed down to a CMO, it is not likely to be adapted by them at a later date.

    So, the creation of this major industry by the growth of outsourcing has numerous good, some not so good, and some potential downsides. I mentioned at the beginning of this column that all work was performed in-house in the “good old days.” What should also be explained is that all excipients and some APIs were, to use an organic chef’s line, “Locally Sourced.” That is, the talc came from a mine in Alabama, starch was from the Midwest, lactose from our dairy states, and so forth. The USP, developed for neighborhood pharmacies to identify and check basic safety of materials, was dependent on American (and sometimes Canadian) suppliers to basically be honest and subject to U.S. law.

    Now take a look at the heparin “problem” that happened a few years back. Most of our heparin is imported from China, which does not (did not, at least) have the same levels of oversight as here from the U.S. FDA. For reference, there was a drought in China, causing a loss of pigs; heparin is derived from the stomach lining of slaughtered pigs, collected by farmers, NOT pharmacists or chemists. The shortfall of actual heparin was made up by adding over-sulfated chondroitin, which is used for joint pain in humans and animals. Heparin is a linear polysaccharide made up of α-l-iduronic acid, β-d-glucuronic acid and a-d-glucosamine repeat units. Chondroitin sulfate is a sulfated glycosaminoglycan (GAG) composed of a chain of alternating sugars (N-acetylgalactosamine and glucuronic acid). Both are seen as equal in older “wet” tests. The older USP ID tests did not differentiate between the two, so a 50/50 mix could not be determined, leading to a number of deaths. [Spoiler alert: easily distinguished by NIRS.]

    The tests, designed as a double-check for local pharmacists, are not optimal for a multinational supply chain. As newer technologies were introduced (e.g., NIRS for raw materials qualification, a staple since 1985), many of these problems, due to inexperience or lack of oversight abroad, can be obviated by moving to NIR or Raman spectrometers for all incoming materials.

    It is expensive and complex when the single-company, even with a multi-site company, moves production to several independent contract locations. What might have been one or two units in a warehouse, now need units in several locations, all validated and operated by different personnel. This carries over to dosage form analysis, and so forth.

    So, in short:
    1. Multiple sites for multiple functions: lower overhead, since larger companies have higher costs; this is spread over the cost for each batch, making them more expensive to produce, when compared with a contracted company. Increased logistics of control, simply from having to interface with multiple sites in different states or countries.

    2. Updating technology of analysis: Initially, analyses may be dispersed, since it is often based on compendial methods. This assures that parallel labs would have parallel methods. The downside is less chance of new technologies introduced into the analysis scheme.

    A potential difficulty is variations in raw materials in differing locales (Pfizer ships materials to its overseas production centers), but, in time, all problems can be overcome, making outsourcing a good trend.


    Emil W. Ciurczak
    DoraMaxx Consulting

    Emil W. Ciurczak has worked in the pharmaceutical industry since 1970 for companies that include Ciba-Geigy, Sandoz, Berlex, Merck, and Purdue Pharma, where he specialized in performing method development on most types of analytical equipment. In 1983, he introduced NIR spectroscopy to pharmaceutical applications, and is generally credited as one of the first to use process analytical technologies (PAT) in drug manufacturing and development.
    Related Searches
    • fda
    • Pharma
    • dosage form development
    • generic
    Suggested For You
    Asymchem Asymchem
    Softweb Solutions Softweb Solutions
    Vetio Animal Health Vetio Animal Health
    Akcea, Pfizer Enter Licensing Agreement for Antisense Therapy  Akcea, Pfizer Enter Licensing Agreement for Antisense Therapy
    Contracting And Outsourcing Agenda Contracting And Outsourcing Agenda
    Pharma Manufacturing: Methods for Real-Time Microbiology Pharma Manufacturing: Methods for Real-Time Microbiology
    The Bioprocessing Trek The Bioprocessing Trek
    Pfizer Invests $500M in Gene Therapy Facility Pfizer Invests $500M in Gene Therapy Facility
    Mylan and Upjohn Join Forces Mylan and Upjohn Join Forces
    Syapse, Pfizer in Oncology Precision Medicine Pact Syapse, Pfizer in Oncology Precision Medicine Pact
    01	Pfizer, Inc. 01 Pfizer, Inc.
    Re-Open Your Tool Chest Re-Open Your Tool Chest
    TILT Biotherapeutics to Collaborate with Merck KGaA and Pfizer TILT Biotherapeutics to Collaborate with Merck KGaA and Pfizer
    Pfizer to Acquire Array BioPharma for $11.4B Pfizer to Acquire Array BioPharma for $11.4B
    Getting PAT into Bioprocessing CMOs Getting PAT into Bioprocessing CMOs

    Related Columns

    • Information Technology
      Life Sciences Strive for Greater Agility

      Life Sciences Strive for Greater Agility

      Embracing real-time drug safety monitoring during and post COVID will continue to propel the industry forward.
      Ronan Brown and Joe Rymsza, IQVIA 03.01.21

    • Biologics, Proteins, Vaccines
      Vaccines and Return-To-Normalcy

      Vaccines and Return-To-Normalcy

      Planning for a future in which COVID-19 won’t simply ‘disappear.’
      Ben Locwin, Contributing Editor 03.01.21

    • Chemistry | Laboratory Testing
      Back to the Future

      Back to the Future

      All that’s Old is New Again.
      Emil W. Ciurczak, DoraMaxx Consulting 03.01.21


    • Biologics, Proteins, Vaccines
      Vaccines 2021

      Vaccines 2021

      Looking at the behavioral economics of vaccinations.
      Ben Locwin, Contributing Editor 01.27.21

    • A Potential “Marriage”

      A Potential “Marriage”

      Initiator companies and generics/CMOs working together.
      Emil W. Ciurczak, DoraMaxx Consulting 11.17.20

    • When Politics and Science Collide

      When Politics and Science Collide

      COVID-19 illustrates why science should always be a principal informer of politics to make better and smarter decisions.
      Ben Locwin, Contributing Editor 11.17.20


    • The Pandemic’s Become an Insurmountable Opportunity

      The Pandemic’s Become an Insurmountable Opportunity

      Every Cloud has a Silver Lining(?)
      Emil W. Ciurczak, Contributing Editor 10.14.20

    • Biologics, Proteins, Vaccines
      It Takes a Vaccine… To End The Pandemic [У нас есть хорошая вакцина]

      It Takes a Vaccine… To End The Pandemic [У нас есть хорошая вакцина]

      Race for the vaccines is heating up.
      Ben Locwin, Contributing Editor 09.09.20

    • cGMP Manufacture
      Keys to Biotech Success

      Keys to Biotech Success

      Four steps emerging biotech companies can take to achieve success
      Thierry Cournez, Head of End-to-End Solutions, MilliporeSigma 06.04.20


    • Analytical Services
      What Happens When the All-Clear Signal is Given?

      What Happens When the All-Clear Signal is Given?

      Maybe 3M had some good ideas?
      Emil W. Ciurczak, DoraMaxx Consulting 06.04.20

    • Almost Like the Olympics:

      Almost Like the Olympics:

      “Smaller, Faster, Smarter”
      Emil W. Ciurczak, DoraMaxx Consulting 05.05.20

    • Rapid Delivery of Medical Countermeasures Amid Pandemic

      Rapid Delivery of Medical Countermeasures Amid Pandemic

      Robert Erwin of iBio discusses the company’s COVID-19 vaccine development efforts and FastPharming manufacturing platform for the rapid delivery of vaccines
      Kristin Brooks, Managing Editor, Contract Pharma 05.05.20


    • The Supply Chain House of Cards

      The Supply Chain House of Cards

      The COVID-19 pandemic exposes pressures on extended global supply chains
      Emil W. Ciurczak, DoraMaxx Consulting 04.01.20

    • Analytical Services | Laboratory Testing
      The Supply Chain, as Developed by IKEA (some assembly required)

      The Supply Chain, as Developed by IKEA (some assembly required)

      Pick One from Column A, Two from Column B, etc.
      Emil W. Ciurczak, DoraMaxx Consulting 03.04.20

    • Coronavirus 2020

      Coronavirus 2020

      What’s The Impact To The World and Industry?
      Ben Locwin, Contributing Editor 03.04.20

    Trending
    • BMS Expands Cell Therapy Manufacturing Capabilities
    • AbbVie Opts To Acquire Mitokinin
    • Bormioli Opens New Glass Research Center
    • WuXi AppTec Completes OXGENE Acquisition
    • Arcline Investment Acquires ChargePoint Technology
    Breaking News
    • Innoforce and dMed Enter Development Collaboration
    • Matica Biotechnology Breaks Ground on Cell and Gene Therapy Site
    • Four Female Leaders Appointed to Cell & Gene CDMO
    • Fusion Pharmaceuticals Acquires IPN-1087
    • Strata Oncology Unveils Strata PATH Trial
    View Breaking News >
    CURRENT ISSUE

    March 2021

    • Hygienic Packaging Technology
    • Trends in Solid Oral Dosage Delivery
    • 5 Reasons Paper Has No Place in Contract Manufacturing
    • Injectable Drug Delivery Trends
    • Pharmaceutical Manufacturing Equipment Trends
    • Oral Solids: Market & Technology Trends
    • Nutraceutical Manufacturing: Meeting the Challenges of Today, Planning for Tomorrow
    • 2021 Contract Manufacturing Survey
    • Small Molecule Development Trends
    • Challenges & Opportunities Facing Small & Emerging Biopharma Companies
    • View More >

    Cookies help us to provide you with an excellent service. By using our website, you declare yourself in agreement with our use of cookies.
    You can obtain detailed information about the use of cookies on our website by clicking on "More information”.

    • About Us
    • Privacy Policy
    • Terms And Conditions
    • Contact Us

    follow us

    Subscribe
    Nutraceuticals World

    Latest Breaking News From Nutraceuticals World

    Study Explains Link Between Probiotic Strains and Children’s Immune Health Benefits
    Maypro Launches Brain Heatlh Ingredient NeuroHD
    Gadot Biochemical Launches New Magnesium Ingredients
    Coatings World

    Latest Breaking News From Coatings World

    Chromaflo Technologies Adds Benjamin Woeste as Territory Sales Manager
    Matt Fogel Named Mule-Hide's Territory Manager – Southern Virginia
    Benjamin Moore Launches COMMAND
    Medical Product Outsourcing

    Latest Breaking News From Medical Product Outsourcing

    Ready Robotics Hires Proven Automation Leaders
    Philips, Disney Join Forces to Reduce Childrens' MRI Anxiety
    FDA OKs Asensus' Senhance for General Surgery
    Contract Pharma

    Latest Breaking News From Contract Pharma

    Innoforce and dMed Enter Development Collaboration
    Matica Biotechnology Breaks Ground on Cell and Gene Therapy Site
    Four Female Leaders Appointed to Cell & Gene CDMO
    Beauty Packaging

    Latest Breaking News From Beauty Packaging

    BizBash Names Unfiltered Experience ‘People's Choice: Best Influencer Event’
    P&G Makes Progress Toward Packaging Circularity in Europe
    Coty Partners with LanzaTech to Introduce Sustainable Ethanol
    Happi

    Latest Breaking News From Happi

    Uoma Beauty Unveils a 'Coming 2 America' Makeup Collaboration
    Coty Partners with LanzaTech to Reduce Its Environmental Impact
    Waterless Beauty, Simplified Routines Shape Clean Beauty at Whole Foods
    Ink World

    Latest Breaking News From Ink World

    Massilly North America Adds Koenig & Bauer MetalStar 3 Metal Decorating Press
    Hydrocarbon Solvents Market to Surpass $8.1 Billion by 2030
    Access Direct Mail Doubles Revenue with SCREEN's Truepress Jet520HD
    Label & Narrow Web

    Latest Breaking News From Label & Narrow Web

    Fort Dearborn Company acquires Hammer Packaging
    Ashland announces PSA price hike in North America
    Arrow Systems and Sihl form flexible packaging partnership
    Nonwovens Industry

    Latest Breaking News From Nonwovens Industry

    Joa Announces Expandable Absorbent Core Wrap Solution
    Principle Business Enterprises Celebrates 60 Years
    Mann+Hummel Invests in Pamlico Air
    Orthopedic Design & Technology

    Latest Breaking News From Orthopedic Design & Technology

    Lincotek Medical Expands Coatings and Additive Capacity
    Spinal Elements Relaunches the Luna XD and Orbit Systems
    Coronavirus Triggers Double-Digit Revenue Dropoff at Smith+Nephew
    Printed Electronics Now

    Latest Breaking News From Printed Electronics Now

    Comercial Kywi Improves Customer Service, Front-Store Operations with Zebra Mobile Solution
    Global Printed Circuit Board Market Projected to Reach $69.32 Billion by 2027
    Global Smart Glass Market to Register 6.8% CAGR Between 2021-28: Grand View Research

    Copyright © 2021 Rodman Media. All rights reserved. Use of this constitutes acceptance of our privacy policy The material on this site may not be reproduced, distributed, transmitted, or otherwise used, except with the prior written permission of Rodman Media.

    AD BLOCKER DETECTED

    Our website is made possible by displaying online advertisements to our visitors.
    Please consider supporting us by disabling your ad blocker.


    FREE SUBSCRIPTION Already a subscriber? Login